Jul 25, 2024, 14:02
Erman Akkus: Should up-front SRS be added to TKI in brain metastatic EGFR/ALK positive NSCLC?
Erman Akkus, Medical Oncologist at Ankara University, shared a paper by Luke R.G. Pike et al. on X:
“Should up-front SRS be added to TKI in brain metastatic EGFR/ALK+ NSCLC?
- Improves time-to-CNS progression HR: 0.63 (0.42 to 0.96), P = .033
- No difference in OS
- More than 20% of patients had >11 brain metastases.”
Source: Erman Akkus/X
Authors: Luke R.G. Pike, Emily Miao, Lillian A. Boe, Tejas Patil, Brandon S. Imber, Nathaniel J. Myall, Erqi L. Pollom, Caressa Hui, Vera Qu, Jacob Langston, Veronica Chiang, Michael Grant, Sarah B. Goldberg, Joshua D. Palmer, Rahul N. Prasad, Tony J.C. Wang, Albert Lee, Catherine A. Shu, Lanyi Nora Chen, Nicholas J. Thomas, Steve E. Braunstein, Brian D. Kavanagh, D. Ross Camidge, Chad G. Rusthoven
Albert Lee
ALK
Brandon S. Imber
Brian D. Kavanagh
cancer
Caressa Hui
Catherine A. Shu
Chad G. Rusthoven
D. Ross Camidge
EGFR
Emily Miao
Erman Akkus
Erqi L. Pollom
Jacob Langston
Joshua D. Palmer
Journal of Clinical Oncology
Lanyi Nora Chen
Lillian A. Boe
Luke R. G. Pike
Michael Grant
Nathaniel J. Myall
Nicholas J. Thomas
NSCLC
OncoDaily
Oncology
Rahul N. Prasad
Sarah B. Goldberg
Steve E. Braunstein
Tejas Patil
Tony J.C. Wang
Vera Qu
Veronica Chiang
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14